423 related articles for article (PubMed ID: 20215534)
1. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
2. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
[TBL] [Abstract][Full Text] [Related]
4. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
Niu G; Li Z; Xie J; Le QT; Chen X
J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
[TBL] [Abstract][Full Text] [Related]
5. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
6. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
8. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
10. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
11. Optical imaging predicts tumor response to anti-EGFR therapy.
Helman EE; Newman JR; Dean NR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2010 Jul; 10(2):166-71. PubMed ID: 20505368
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib enhances radiotherapeutic effects of
Xia L; Peng H; Zhiqiang L; Xiaoli Z
Nucl Med Biol; 2017 May; 48():63-68. PubMed ID: 28254656
[TBL] [Abstract][Full Text] [Related]
15. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
17. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.
Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA
Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356
[TBL] [Abstract][Full Text] [Related]
18. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.
Cai W; Chen K; He L; Cao Q; Koong A; Chen X
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214
[TBL] [Abstract][Full Text] [Related]
19. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
20. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
